Sponsors
The bill accelerates patient access to lower‑cost generics and reduces public drug spending by narrowing some patent protections, but it raises risks to innovators' revenues and increases legal uncertainty that could dampen future incremental drug development.
Patients who use prescription drugs (including people with chronic conditions and beneficiaries of Medicaid and Medicare) are likely to get lower-cost generic and biosimilar alternatives sooner because the bill shortens effective exclusivity periods.
Federal and state health programs and taxpayers could save money as earlier generic/biosimilar entry increases competition and lowers drug prices.
USPTO review and potential new guidance may reduce issuance of low‑quality or duplicative patents, improving patent system integrity and reducing some bad patents that can impede competition.
Innovator drug companies (including small biopharma firms) may face weakened patent protections and reduced expected revenue from later-listed patents unless they can prove distinctness, which could reduce returns on some drug investments.
Both brand and generic drug firms are likely to face increased litigation over what counts as "patentably distinct," raising legal costs and business uncertainty.
If courts apply the presumption broadly, incentives to invest in follow‑on improvements and incremental innovation could decline, potentially slowing some incremental drug development.
Based on analysis of 2 sections of legislative text.
Creates a presumption that later-expiring patents on the same drug are disclaimed unless the patentee proves the later patent claims a distinct invention, and orders a USPTO review of examination practices.
Introduced January 31, 2025 by Patrick Ryan · Last progress January 31, 2025
Changes to patent law would make it harder for later-expiring patents on the same drug or biologic to extend market exclusivity. The bill creates a legal presumption that a patentee has disclaimed patent term for later-expiring patents covering the same product unless the patentee proves those later patents claim a different invention, and it requires the USPTO Director to review examination practices and report recommendations within one year.